ADVANCING POORLY SOLUBLE DRUG DELIVERY: NANOTECHNOLOGY STRATEGIES AND NANOMORPH TECHNOLOGY

Poor aqueous solubility remains a critical barrier in pharmaceutical development, affecting bioavailability and therapeutic efficacy of numerous drug candidates. Nanotechnology emerges as a transformative approach, utilizing nanoparticles (1-1000 nm) to dramatically enhance dissolution rates and saturation solubility via increased surface area. This review synthesizes key nanoparticle production techniques, including wet milling, high-pressure homogenization, emulsification, and precipitation methods like PCA, RESS, SFL, and EPAS, which convert coarse crystalline drugs into stable nanosuspensions or amorphous forms.
Among commercialized platforms, Nanomorph technology stands out for its precipitation- based conversion of poorly soluble drugs into amorphous nanoparticles using water-miscible solvents and polymer stabilizers. This process prevents aggregation, yielding redispersible powders suitable for diverse dosage forms, including orals and injectables. Compared to traditional methods, Nanomorph offers superior stability without Ostwald ripening, as evidenced by enhanced bioavailability in models like danazol (from 5.2% to 82.3%). Other innovations such as Dissocubes, Nanocrystal, Nanoedge, Nanopure, Crititech, and Nanocochleate further exemplify nanotechnology's versatility, bypassing chemical modifications' drawbacks like cost and toxicity risks.